{
  "ticker": "JNJ",
  "target_date": "2025-03-14",
  "actual_date": "2025-03-14",
  "collected_at": "2025-12-08T11:31:08.267685",
  "price": {
    "open": 158.56,
    "high": 159.57,
    "low": 157.57,
    "close": 159.2388153076172,
    "volume": 6235800,
    "change_1d_pct": -0.11,
    "change_7d_pct": -1.4,
    "change_30d_pct": 7.35
  },
  "technicals": {
    "rsi_14": 47.61,
    "sma_20": 159.62,
    "sma_50": 150.63,
    "macd": 2.891,
    "macd_signal": 3.67,
    "macd_histogram": -0.779,
    "bb_upper": 166.88,
    "bb_lower": 152.36,
    "price_vs_sma20_pct": -0.24,
    "price_vs_sma50_pct": 5.72,
    "volume_ratio": 0.65
  },
  "fundamentals": {
    "market_cap": 488960393216,
    "pe_ratio": 19.589527,
    "forward_pe": 19.145988,
    "price_to_book": 6.159817,
    "price_to_sales": 5.3061934,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.34,
    "pct_from_52w_low": 44.26
  },
  "macro": {
    "spy": {
      "price": 557.92,
      "change_1d_pct": 2.07,
      "change_7d_pct": -1.73
    },
    "vix": {
      "level": 21.77,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.31
    },
    "dollar_index": {
      "level": 103.72
    },
    "gold": {
      "price": 2994.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
      "source": "Yahoo",
      "datetime": 1741967105,
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=19ed207271b2b4ff27c550e6c84312afac9dfd8bc7087d67772ecf2510c28de6"
    },
    {
      "headline": "Genmab: GEN3014's Demise And Implications For The HexaBody Platform",
      "source": "SeekingAlpha",
      "datetime": 1741962624,
      "summary": "Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.",
      "url": "https://finnhub.io/api/news?id=cbc0f55f861454d4980ed5a0f258ea890aacfbb8eee99d8d6091e3e274e9c247"
    },
    {
      "headline": "Hostage to Legal Decisions \u2013 Here\u2019s Why Jim Cramer Gave Up on Johnson & Johnson (JNJ)",
      "source": "Yahoo",
      "datetime": 1741962391,
      "summary": "We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed 12 months ago during his show on March 18, 2024. On the most recent episode of Mad [\u2026]",
      "url": "https://finnhub.io/api/news?id=3de97f087b89691523d045c979ba225d42c0774de337a84077c840d443590da1"
    },
    {
      "headline": "Zimmer Biomet Focuses on Innovation Amid Growing Competition",
      "source": "Yahoo",
      "datetime": 1741960500,
      "summary": "Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.",
      "url": "https://finnhub.io/api/news?id=7473313943970018112aa3aa3d79531f974cef5f69c01f3e23ee4fc249347670"
    },
    {
      "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
      "source": "Yahoo",
      "datetime": 1741944600,
      "summary": "Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.",
      "url": "https://finnhub.io/api/news?id=647713b5d7a0f754f1eb422329ff7d6f6b53fbeb68dfd1d173d7250004069c1b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    },
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}